Mustang Bio, a Fortress Biotech Company, and St. Jude Children’s Research Hospital have entered into an exclusive worldwide license agreement for the development of a first-in-class ex vivolentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (“X-SCID”), also known as bubble boy disease. X-SCID is the most common form of severe combined immunodeficiency, affecting approximately one in 50,000 to 100,000 newborns worldwide. The therapy, which includes a low dose...